Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8VQ2

HSV1 polymerase ternary complex with dsDNA and compound 44

This is a non-PDB format compatible entry.
Summary for 8VQ2
Entry DOI10.2210/pdb8vq2/pdb
DescriptorDNA polymerase, DNA (5'-D(P*TP*GP*GP*TP*AP*GP*GP*GP*GP*AP*AP*GP*GP*AP*T)-3'), DNA (5'-D(P*AP*TP*CP*CP*TP*TP*CP*CP*CP*CP*TP*AP*C)-3'), ... (4 entities in total)
Functional Keywordsherpesvirus polymerase complex inhibitor, transferase
Biological sourceHuman alphaherpesvirus 1 (Herpes simplex virus type 1)
More
Total number of polymer chains6
Total formula weight277265.65
Authors
Hayes, R.P.,Heo, M.R.,Plotkin, M. (deposition date: 2024-01-17, release date: 2024-08-28)
Primary citationPlotkin, M.A.,Labroli, M.,Schubert, J.,Shaw, A.,Schlegel, K.S.,Berger, R.,Cooke, A.J.,Hayes, R.P.,Armacost, K.A.,Kinek, K.,Krosky, P.,Burlein, C.,Meng, S.,DiNunzio, E.,Murray, E.M.,Agrawal, S.,Madeira, M.,Flattery, A.,Yao, H.,Leithead, A.,Rose 2nd, W.A.,Cox, C.,Tellers, D.M.,McKenna, P.M.,Raheem, I.
Discovery of Broad-Spectrum Herpes Antiviral Oxazolidinone Amide Derivatives and Their Structure-Activity Relationships.
Acs Med.Chem.Lett., 15:1232-1241, 2024
Cited by
PubMed Abstract: Herpesvirus infections are ubiquitous, with over 95% of the adult population infected by at least one strain. While most of these infections resolve without treatment in healthy individuals, they can cause significant morbidity and mortality in immunocompromised, stem cell, or organ transplant patients. Current nucleoside standards of care provide meaningful benefit but are limited due to poor tolerability, resistance, and generally narrow spectrum of activity. Herpesviruses share a conserved DNA polymerase, the inhibition of which is validated as an effective strategy to disrupt viral replication. By utilizing a non-nucleoside inhibitor of the viral DNA polymerase, we sought to develop agents covering multiple herpesviruses (e.g., CMV, VZV, HSV1/2, EBV, and HHV6). Herein is described the invention of an oxazolidinone class of broad-spectrum non-nucleoside herpes antiviral inhibitors. A lead compound () with potent biochemical and broad-spectrum cellular activity was found to be efficacious in murine models against both HSV-1 and CMV infection.
PubMed: 39140041
DOI: 10.1021/acsmedchemlett.4c00117
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.829 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon